5-(N,N-Hexamethylene)-amiloride

Cat. No.:	HY-128067			
CAS No.:	1428-95-1			
Molecular Formula:	C ₁₂ H ₁₈ ClN ₇ O			
Molecular Weight:	311.77			
Target:	Sodium Channel; HIV; Apoptosis			
Pathway:	Membrane Transporter/Ion Channel; Anti-infection; Apoptosis			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (320.75 mM; Need ultrasonic)							
		Mass Solvent 1 mg 5 r Concentration		5 mg	10 mg			
	Preparing Stock Solutions	1 mM	3.2075 mL	16.0375 mL	32.0749 mL			
		5 mM	0.6415 mL	3.2075 mL	6.4150 mL			
		10 mM	0.3207 mL	1.6037 mL	3.2075 mL			
	Please refer to the solubility information to select the appropriate solvent.							
In Vivo	0 >> 45% saline							
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.67 mM); Clear solution							
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (6.67 mM); Clear solution							

DIOLOGICAL ACTIV	
Description	5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na ⁺ /H ⁺ exchanger inhibitor, which decreases the intracellular pH (pH _i) and induces apoptosis in leukemic cells. 5-(N,N-Hexamethylene)- amiloride (Hexamethylene amiloride) is also an inhibitor of the HIV-1 Vpu virus ion channel and inhibits mouse hepatitis virus (MHV) replication and human coronavirus 229E (HCoV229E) replication in cultured L929 cells with EC ₅₀ s of 3.91 µM and 1.34 µM, respectively ^{[1][2]} .
IC ₅₀ & Target	HIV-1

Product Data Sheet

N[~]

NH₂

CI

 NH_2



In Vitro

5-(N,N-Hexamethylene)-amiloride inhibits human cardiac ion channels hERG (in CHO cells), Nav1.5 and Cav1.2 (in EHK293 cells) with of 3.3 μM, 30 μM, 8.3 μM, respectively, inelectrophysiology assays^[3].

5-(N,N-Hexamethylene)-amiloride (1 μM; 0-60 min; 37 ⊠) exhibits microsomal stability, (1 μg/mL; 4.2 h; 37 ⊠) shows mouse plasma stability and plasma protein binding, (20 μM; 4 h) displays Caco-2 cell permeability, cardiac ion channel activity^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[3]

Cell Line:	In vitro pharmacokinetics properties
Concentration:	1μM
Incubation Time:	0-60 min

Result:

	t _{1/2} (min)	CL _{int} (μL/min/mg protein)	CL _{int} (μL/min/mg protein)
Human liver microsomers in vitro	73	24	74
Mouse liver microsomers in vitro	2.4	726	2243

In Vivo

5-(N,N-Hexamethylene)-amiloride (2.5 mg/kg; i.v.; single dose) shows short half-life and lowly oral bioavailability of 4.5%^[3]. In vivo pharmacokinetics in mice or rat model^[3]

Dosage: 2.5 mg/kgAdministration: Intravenous injection; single does; collected 10 min and 60 min after treatment.

	t _{1/2} (h)	Plasma CL _{int} (mL/min/kg)	Plasma V _{ss} (L/kg)	Plasma AUC ₀₋ _{inf} (h∙µM)	B/P ratio	Blood CL (mL/min/kg)	Blood V _{ss} (L/kg)
Female Balb/c mice	0.62	86	2.0	1.5	1.5	59	1.4
Sprague Dawley rats	3.2	83.5	5.3	1.6	1.8	46.2	2.9
	% IV dose excreted in urine (0-24 h)	Renal Blood CL (mL/min/kg)	Non-Renal Blood CL (mL/min/kg)				
Sprague Dawley rats	0.5	0.2	46.0				

Note: B/P means blood-to-plasma partitioning ratio; female Balb/c mice (17-27 g, non-fasted); male Sprague Dawley rats (238-325 g, overnight-fasted).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

• Sci Adv. 2023 Aug 9;9(32):eadh2413.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. Buckley BJ, et al. Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride. Bioorg Med Chem. 2021 May 1;37:116116.

[2]. Rich IN, et al. Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. Blood. 2000 Feb 15;95(4):1427-34.

[3]. Wilson L, et al. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology. 2006 Sep 30;353(2):294-306. Epub 2006 Jul 3.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA